The purpose of the study is to describe medical care strategies implemented by healthcareestablishments for patients affected by COVID-19
Coronavirus infection (SARS-Cov2), very contagious, is benign in the most cases but can
be complicated by an acute respiratory distress syndrome, for which an invasive
mechanical ventilation in resuscitation is necessary with an important mortality rate.
This infection is about an important health crisis with a fast saturation of the health
system.
In front of the novelty of this virus, any effective treatment has been demonstrated in
humans and researches have accelerated as this pandemic continues.
First available results, in chinese population, have not demonstrated superiority of the
Lopinavir/Ritonavir association versus standard care (Cao et al. 2020). In a randomized
study in 62 chinese patients, Chen et al. seems to find a clinical efficacy of the
Hydroxychloroquine compared to placebo. Gautret et al. has also found a decreased viral
load in nasopharyngeal swabs in patients affected by COVID-19, treated by
Hydroxychloroquine and by the association of Hydroxychloroquine-Azythromycine. However,
these preliminary results doesn't allow to conclue on the efficacy against COVID-19.
Currently, any treatment in particular is recommanded for patients affected by COVID-19.
Randomized studies on a larger scale and greater rigor at national and european level are
in process to determine the efficacy of several treatments.
Pending results of these studies, healthcare establishments had to adapt and strategize
to take care their patients. These strategies have rapidely evolved during this pandemy,
in terms of the therapeutic clinical studies opening, the acquisition of new knowledges
on COVID-19, and treatments.
Screening : All patients with a COVID-19 diagnosis who have been treated in 2020 in
participant establishements will be included in the HOPICOV study.
Enrolment : On discharge from hospital, an information notice will be delivered to the
patient (or at his close relative / his legal guardian) to allow him to exert his right
to oppose his collection data identified as part of the treatment. Otherwise, this
information might be send by letter after his discharge.
All participating centers will be encouraged to enter data as things progress to allow
interim analysis and scientific communication.
Other: Data collection
Some data will be collected for all patients included :
- specific treatment administered in COVID unit
- dosages of treatment
- inclusion in clinical trials
Evolution of French recommendations and the publication of scientific articles
Inclusion Criteria:
- Any adult patient admitted to the establishment for treatment for a SARS-Cov2
infection
- Positive RT-PCR or a scanner suggestive of COVID-19 during the stay, or with a
positive serology (even if carried out after the patient's discharge)
- Hospitalization > 24h
- Patients receiving any type of care, whether it is recommended standard care or
off-label treatment as part of a therapeutic clinical trial or outside the scope of
clinical research
Exclusion Criteria:
- Opposition to the use of data following written patient information
- Patient transferred from another hospital to continue COVID care and whose initial
care data is not available
Hospital Center Emile Roux
Le Puy-en-Velay, France
Not Provided